MIRA (MIRA Pharmaceuticals Inc.) stock: $0.57, $24.0M market cap, $8.1M cash, $15.9M EV, $28.5M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA, the “Company”, “we”, “us”) is a clinical-stage pharmaceutical development company advancing a pipeline of novel oral therapeutics targeting neurologic, neuropsychiatric, metabolic, and addiction-related disorders.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
chemotherapy-induced peripheral neuropathy(Stage not disclosed)
Catalysts
— None
Status note Oral selective NMDA receptor modulator. Phase 1 single- and multiple-ascending-dose studies in healthy volunteers completed; active IND.
MIRA-55
Preclinical · ActiveModality: oral small molecule
Target CB2
Indications
chronic inflammatory pain(Stage not disclosed)
Status note Potential non-opioid therapy. Advancing toward IND-enabling studies; formulation optimization completed, CMC activities and exploratory repeated-dose toxicology ongoing.
SKNY-1
Preclinical · ActiveModality: oral small molecule
Target CB1 / CB2 / MAO-B
Partnerships SKNY Pharmaceuticals (related party; license acquired September 2025; amended license June 2026)
Indications
obesity(Stage not disclosed)
Status note Preclinical obesity candidate designed to modulate CB1, CB2, and MAO-B pathways. Advancing toward IND-enabling studies.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.